CeriBell, Inc. (NASDAQ:CBLL) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of CeriBell, Inc. (NASDAQ:CBLL) have received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $24.6667.

A number of equities analysts recently issued reports on CBLL shares. BTIG Research reissued a “buy” rating and set a $30.00 price target on shares of CeriBell in a report on Wednesday, January 28th. TD Cowen reiterated a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. Finally, Canaccord Genuity Group boosted their target price on CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a report on Wednesday, December 17th.

CeriBell Stock Down 4.0%

CBLL traded down $0.74 on Friday, reaching $17.66. The company’s stock had a trading volume of 142,959 shares, compared to its average volume of 331,271. The company has a market capitalization of $664.72 million, a price-to-earnings ratio of -12.01 and a beta of 1.12. CeriBell has a fifty-two week low of $10.01 and a fifty-two week high of $24.33. The company has a quick ratio of 9.35, a current ratio of 9.73 and a debt-to-equity ratio of 0.13. The stock has a 50 day moving average of $19.77 and a two-hundred day moving average of $17.14.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.07. The business had revenue of $24.78 million during the quarter, compared to analysts’ expectations of $23.95 million. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. As a group, analysts forecast that CeriBell will post -2.46 EPS for the current fiscal year.

Insider Activity at CeriBell

In other CeriBell news, Director Josef Parvizi sold 25,000 shares of the company’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $22.94, for a total transaction of $573,500.00. Following the completion of the transaction, the director owned 747,652 shares in the company, valued at approximately $17,151,136.88. This represents a 3.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Xingjuan Chao sold 79,000 shares of CeriBell stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $21.27, for a total transaction of $1,680,330.00. Following the completion of the sale, the chief executive officer directly owned 741,248 shares in the company, valued at approximately $15,766,344.96. The trade was a 9.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 203,627 shares of company stock worth $4,156,660 in the last 90 days. Corporate insiders own 20.10% of the company’s stock.

Hedge Funds Weigh In On CeriBell

A number of large investors have recently modified their holdings of the business. Russell Investments Group Ltd. grew its holdings in CeriBell by 41.4% during the fourth quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock worth $64,000 after acquiring an additional 854 shares during the period. Caitong International Asset Management Co. Ltd grew its stake in shares of CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after purchasing an additional 1,231 shares during the period. Ameritas Investment Partners Inc. increased its holdings in shares of CeriBell by 97.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock valued at $48,000 after purchasing an additional 1,256 shares in the last quarter. Deutsche Bank AG lifted its stake in shares of CeriBell by 1.7% in the fourth quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock valued at $1,868,000 after purchasing an additional 1,393 shares during the period. Finally, Royal Bank of Canada grew its position in CeriBell by 10.8% during the fourth quarter. Royal Bank of Canada now owns 15,588 shares of the company’s stock worth $342,000 after buying an additional 1,514 shares during the period.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.